Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-02-06 4:45 pm Purchase | 2026-02-03 | 13G | Perspective Therapeutics, Inc. CATX | TCG Crossover GP II, LLC | 7,915,567 6.900% | 7,915,567![]() (New Position) | Filing History |
| 2026-02-06 4:42 pm Purchase | 2026-01-30 | 13G | ALX Oncology Holdings Inc. ALXO | TCG Crossover GP II, LLC | 13,011,849 9.900% | 13,011,849![]() (New Position) | Filing History |
| 2026-02-02 4:13 pm Purchase | 2026-01-26 | 13G | Surrozen, Inc. SRZN | TCG Crossover GP II, LLC | 1,274,010 11.400% | 1,274,010![]() (New Position) | Filing History |
| 2026-01-15 4:19 pm Purchase | 2026-01-09 | 13G | Century Therapeutics, Inc. IPSC | TCG Crossover GP II, LLC | 17,754,430 9.900% | 17,754,430![]() (New Position) | Filing History |
| 2025-11-14 4:23 pm Sale | 2025-09-30 | 13G | Tango Therapeutics, Inc. TNGX | TCG Crossover GP II, LLC | 8,536,196 6.300% | -1,964,416![]() (-18.71%) | Filing History |
| 2025-11-14 4:23 pm Sale | 2025-09-30 | 13G | Nektar Therapeutics NKTR | TCG Crossover GP II, LLC | 0 0.000% | -1,933,333![]() (Position Closed) | Filing History |
| 2025-11-14 4:23 pm Sale | 2025-09-30 | 13G | Cidara Therapeutics, Inc. CDTX | TCG Crossover GP II, LLC | 0 0.000% | -1,005,901![]() (Position Closed) | Filing History |
| 2025-11-14 4:18 pm Purchase | 2025-10-22 | 13G | Alector, Inc. ALEC | TCG Crossover GP II, LLC | 10,000,000 9.200% | 10,000,000![]() (New Position) | Filing History |
| 2025-10-17 4:29 pm Purchase | 2025-10-10 | 13G | Monte Rosa Therapeutics, Inc. GLUE | TCG Crossover GP II, LLC | 4,427,705 7.200% | 4,427,705![]() (New Position) | Filing History |
| 2025-09-18 4:24 pm Purchase | 2025-09-12 | 13G | LB Pharmaceuticals Inc Common Stock LBRX | TCG Crossover GP II, LLC | 1,745,015 7.800% | 1,745,015![]() (New Position) | Filing History |
| 2025-08-14 4:14 pm Purchase | 2025-06-30 | 13G | Nektar Therapeutics NKTR | TCG Crossover GP II, LLC | 1,933,333 9.300% | 596,910![]() (+44.66%) | Filing History |
| 2025-05-15 4:34 pm Sale | 2025-03-31 | 13G | Adverum Biotechnologies, Inc. ADVM | TCG Crossover GP II, LLC | 1,871,482 8.900% | -204,875![]() (-9.87%) | Filing History |
| 2025-05-15 4:34 pm Unchanged | 2025-03-31 | 13G | Dianthus Therapeutics, Inc. DNTH | TCG Crossover GP II, LLC | 1,501,624 4.700% | 0 (Unchanged) | Filing History |
| 2025-01-03 4:08 pm Purchase | 2024-12-27 | 13G | RAPT Therapeutics, Inc. RAPT | TCG Crossover GP II, LLC | 1,649,139 9.990% | 1,649,139![]() (New Position) | Filing History |
| 2024-12-03 4:34 pm Purchase | 2024-11-26 | 13G | Cidara Therapeutics, Inc. CDTX | TCG Crossover GP II, LLC | 1,005,901 9.200% | 1,005,901![]() (New Position) | Filing History |
| 2024-11-22 4:41 pm Purchase | 2024-11-15 | 13G | Dianthus Therapeutics, Inc. DNTH | TCG Crossover GP II, LLC | 1,501,624 5.100% | 1,501,624![]() (New Position) | Filing History |
| 2024-11-20 4:24 pm Purchase | 2024-11-13 | 13G | Tango Therapeutics, Inc. TNGX | TCG Crossover GP II, LLC | 10,500,612 9.800% | 10,500,612![]() (New Position) | Filing History |
| 2024-11-13 4:27 pm Sale | 2024-09-30 | 13G | Mineralys Therapeutics, Inc. MLYS | TCG Crossover GP II, LLC | 2,470,265 5.000% | -714,920![]() (-22.45%) | Filing History |
| 2024-11-13 4:21 pm Sale | 2024-09-30 | 13G | Astria Therapeutics, Inc. ATXS | TCG Crossover GP II, LLC | 2,761,861 4.900% | -1,607,067![]() (-36.78%) | Filing History |
| 2024-11-07 4:27 pm Purchase | 2024-10-31 | 13G | EyePoint Pharmaceuticals, Inc. EYPT | TCG Crossover GP II, LLC | 3,572,335 5.200% | 3,572,335![]() (New Position) | Filing History |

